Latest studies
- Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCGermany - AuthorisedTherapeutic exploratory (Phase II)
Proof-of-principle study of inhaled pulmonary surfactant in patients with Idiopathic Pulmonary Fibrosis (INSURF-IPF)
This study explores a new inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if a special lung surfactant can improve how well your lungs work. Researchers will monitor lung function and safety in adults with IPF.
Idiopathic pulmonary fibrosisGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Evaluation of the feasibility of PD L 506 for stereotactic interstitial photodynamic therapy (iPDT) in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma
This study is looking at a new way to treat a type of brain cancer called glioblastoma. It uses a special light treatment to target cancer cells. Researchers want to see if this treatment is safe and practical for adult patients who have recently been diagnosed.
GlioblastomaGermany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study in healthy men to test whether zongertinib influences the amount of 4 other medicines (dabigatran, rosuvastatin, metformin, and furosemide) in the blood
This study looks at how a new medicine, zongertinib, might affect how your body handles other common medicines like dabigatran, rosuvastatin, metformin, and furosemide. We're testing this in healthy men to see if zongertinib changes the amount of these other medicines in their blood.
Pharmacokinetic trialGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)
This study is for people with a certain type of advanced lung cancer that has stopped responding to a previous treatment called osimertinib. It tests a new combination of two drugs, tepotinib and osimertinib, to see if it can shrink tumours.
Lung CancerGermany - Ongoing, recruitingTherapeutic use (Phase IV)
Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia
This study is looking at a new way to lower 'bad' cholesterol (hypercholesterolemia). It compares a new medicine called Inclisiran with usual treatments, to see if it's safe and helps people feel better and reach their cholesterol goals.
HypercholesterolemiaGermany - AuthorisedTherapeutic confirmatory (Phase III)
High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial
This study looks at using strong steroid medicines to treat a type of stroke in children called focal cerebral arteriopathy (FCA). Researchers want to see if these medicines can reduce the inflammation in blood vessels and improve children's recovery.
Focal cerebral arteriopathy and childhood strokeFocal cerebral arteriopathy (FCA) is an inflammatory vessel wall diseaseprovoked by infection.Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Sjögren’s SyndromeGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new medicine, AMX0035, for people with Motor Neurone Disease (ALS). It aims to see if the medicine can slow down the disease's progression over 48 weeks, compared to a dummy medicine.
Amyotrophic Lateral Sclerosis (ALS)Germany - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaGermany - RecruitingPHASE3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
This study looks at an inhaled medicine called treprostinil for people with progressive pulmonary fibrosis. It aims to see if it's safe and effective in slowing down this lung condition over 52 weeks. Half get the medicine, half get a dummy treatment.
Progressive Pulmonary FibrosisInterstitial Lung DiseaseGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
This study is testing a new medicine, NNC0487-0111, for people with type 2 diabetes. It's looking at different ways to take the medicine (once a week shot or once a day pill) to see how safe and effective it is at controlling blood sugar.
Type 2 DiabetesGermany - RecruitingPHASE2, PHASE3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This study looks at switching from one existing medicine, Bulevirtide, to a new one, Brelovitug, for people with long-term Hepatitis D. Researchers want to see if the new medicine is safe and works better.
Chronic Hepatitis DGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immunemediated thrombotic thrombocytopenic purpura
This study is testing a new way to treat a rare blood disorder called TTP. It looks at whether a medicine called Cablivi, along with other treatments, can help people with TTP get better without needing a common but intensive procedure called plasma exchange.
Thrombotic Thrombocytopenic PurpuraGermany - RecruitingPHASE3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
This study is testing a new medicine called iptacopan for people aged 12-60 with a kidney disease called C3 Glomerulopathy (C3G). It aims to see if the medicine is safe and helps improve kidney function compared to a dummy pill.
C3GGermany - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
Metastatic Non-Small Cell Lung CancerGermany - Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
This study looks at how a drug called elafibranor works for people with a rare liver disease called Primary Biliary Cholangitis (PBC) in everyday life. Researchers will check its effects, how safe it is, and how well people tolerate it over about five years.
Primary Biliary CholangitisGermany - RecruitingPHASE3
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
This study looks at a new drug called Leriglitazone for adult men with a brain condition called cerebral adrenoleukodystrophy (cALD). Researchers want to see if it's safe and helps improve or slow down the disease.
Cerebral Adrenoleukodystrophy (cALD)Germany - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma
This study is testing a new medicine, Atuliflapon, for adults whose moderate-to-severe asthma isn't well controlled by their usual treatments. We want to see if it reduces asthma flare-ups and improves breathing, compared to a dummy pill, over 12 weeks.
Moderate-to-Severe Uncontrolled AsthmaGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
This study looks at two medicines, Stelara and Guselkumab, for young people with a type of arthritis called juvenile psoriatic arthritis. It checks how well they work, how safe they are, and how the body handles them.
Juvenile psoriatic arthritisGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
This study is testing a new medicine, batoclimab, for active Thyroid Eye Disease (TED). We want to see if it can help reduce bulging eyes (proptosis) and improve other symptoms, compared to a dummy medicine, in adults with TED.
Thyroid Eye Disease (TED)Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
This study is comparing a new medicine, JPB898, to a licensed cancer drug called Opdivo. Both are used with another drug, Yervoy, to treat advanced melanoma, a serious type of skin cancer. The aim is to see if JPB898 works just as well and is as safe as Opdivo.
Advanced (unresectable/metastatic) melanomaGermany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants
This study is looking at how a new medicine, called Enpatoran, affects the electrical activity of your heart. It's for healthy people aged 18 and over, and it's one of the first tests in humans to make sure the medicine is safe and doesn't cause heart problems.
HealthyGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Giant cell arteritis (GCA)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment
This study is looking into a new medication (BI 706321) for Crohn's disease. It aims to see if it's safe and effective when taken alongside an existing treatment called Stelara, and how it works in the body.
Crohn`s Disease (CD)Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also know as BAX930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)
This study is looking at the long-term safety and helpfulness of a medicine called TAK-755 for people with a rare blood disorder called congenital TTP. It also checks how well TAK-755 prevents TTP episodes in those taking it regularly.
Congenital Thrombotic thrombocytopenic purpura (cTTP)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
This study is checking a new treatment called Immukine alongside usual care for a serious fungal infection in the blood called candidemia. Researchers want to see if it makes people get better faster and how safe it is.
CandidemiaGermany - RecruitingPHASE3
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This study is for people with chronic Hepatitis D (HDV) whose current medicine, bulevirtide, isn't fully controlling the virus. It will test if a new combination of medicines, tobevibart and elebsiran, works better. It's a key step in finding more effective treatments.
Viral HepatitisGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia
This study looks into a new treatment for chronic lymphocytic leukaemia (CLL) that has come back or is hard to treat. It combines a drug called belimumab with existing treatments. Researchers want to see if this combination can get rid of all signs of the cancer in the blood.
refractory or relapsed chronic lymphocytic leukemiaGermany - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaGermany - Not yet recruiting
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The LOVE Study is tracking people with fatty liver disease (MASLD, MetALD, ALD) over several years. Its goal is to better understand how these conditions progress and to find simpler ways to check liver health without needing a liver biopsy. This could lead to earlier diagnosis and better care.
Steatotic Liver DiseaseMASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)Steatotic Liver Disease of Mixed Origin (MetALD)ALD - Alcoholic Liver DiseaseGermany - Active not recruitingPHASE2
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
This study looks at the long-term effects of a drug called GB002 (seralutinib) for people with Pulmonary Arterial Hypertension (PAH). Participants have already been part of a previous GB002 study. It's an open-label study, meaning everyone knows they are receiving the drug.
Pulmonary Arterial HypertensionGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Interventional, randomized, double-blind, parallel-group, placebo-controlled, dose-finding trial of Lu AG09222 for the prevention of migraine in participants with episodic and chronic migraine. Lundbeck trial no: 20297A
This study is testing a new medicine, Lu AG09222, to see if it can help prevent migraines. It's for people who get migraines often, including those with episodic (comes and goes) and chronic (very frequent) migraine. Researchers want to find the best dose to reduce migraine days.
MigraineGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)
This study looks at a new medicine called paltusotine for people with acromegaly. It's a long-term study to see how safe the medicine is and if it works well over time, especially noting any side effects people might have.
AcromegalyGermany - RecruitingPHASE4
Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
This study is looking at a new treatment called ILUVIEN® for children and teenagers aged 6-17 with a specific type of eye swelling called uveitis. We want to see how safe and effective this tiny eye implant is at reducing swelling and improving eyesight.
Non-infectious Uveitis Affecting the Posterior Segment of the EyeGermany - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.
AL AmyloidosisGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis
This study is testing a new medicine, upadacitinib, for giant cell arteritis (GCA). Researchers want to see if it can help people stay well and reduce the need for steroid medicines, comparing it to a dummy medicine.
Giant Cell ArteritisGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
This study looks at a new drug, BB-1701, for advanced breast cancer that has HER2 markers. It aims to find the best dose and check how safe and effective it is for patients who've already had treatment.
HER2 positive or HER2-low metastatic breast cancerGermany - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)Germany - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
Prostatic NeoplasmsGermany - RecruitingPHASE4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
This study looks at the best time to treat a rare twin pregnancy problem called TRAP sequence. We're comparing treating it early (12-14 weeks) versus later (16-19 weeks) to see which approach works better for the healthy twin. It's a randomised trial, meaning timing is decided by chance.
Twin Reversal Arterial Perfusion SyndromeGermany - Active not recruitingPHASE3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
This study looks at whether fezolinetant can reduce hot flashes in women with breast cancer who are having hormone therapy. These hot flashes are a common side effect, and current treatments like HRT aren't suitable. We want to see if fezolinetant helps more than a dummy pill.
Hot FlashesGermany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2D
This early-stage study is for people with type 2 diabetes. It's looking at how a new medicine, NEX-22A, moves through the body. The main goal is to understand how the body handles this new treatment.
Type 2 diabetesGermany - RecruitingPHASE4
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
This study looks into why some breast cancers stop responding to treatment. We will examine tissue and blood samples from patients with specific types of breast cancer to understand how the cancer becomes resistant and find new ways to help them.
Breast CancerGermany - RecruitingPHASE3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
This study looks at a new way to treat a specific type of leukaemia (AML) with a gene change called IDH1. It adds a drug called venetoclax to standard treatment (ivosidenib and azacitidine) to see if it works better. It's for patients who can't have strong chemotherapy.
Acute Myeloid LeukemiaGermany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn about the safety of BAY 3283142 in people with mild to moderate high blood pressure
This study is looking at a new medicine called BAY 3283142. It’s for adults who have slightly high blood pressure and ongoing kidney problems. We want to see how safe the medicine is and if it causes any side effects at different doses.
Chronic kidney diseaseGermany - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVGermany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study to Evaluate the Effects of Various Degrees of Hepatic Impairment on the Pharmacokinetics of A Single Subcutaneous Dose Of RO7434656, an Antisense Inhibitor of Complement Factor B
This study is looking at how a new medicine, called RO7434656, is handled by the body in people with different levels of liver problems. It's a very early stage study to understand how this medicine works and whether liver health affects it.
Hepatic ImpairmentGermany